Robert Levak

Mr. Robert Levak joined the Phoenix Molecular Designs Board of Directors in March 2021. Robert brings over 22 years of experience in oncology with 18 ½ years in biotech commercialization - marketing and sales including new product planning (Avastin, Perjeta, Kadcyla, Adcetris and Tukysa), in-line marketing (Adcetris), sales and sales management (Herceptin, Tarceva, Tukysa), diagnostic and competitive strategy (Adcetris, Tukysa) and early pipeline commercial strategy. At Seagen Inc. he led the initial Global Marketing for tucatinib, ladiratuzumab vedotin and other pipeline programs.

Robert was also the Commercial lead on the $614M Cascadian acquisition driven by the market valuation of tucatinib and the $2B licensing deal with Immunomedics for Sacituzumab govitecan. Robert is the Head of Global Marketing, Oncology at Zymeworks Inc. where he oversees strategic commercial development of ZW-25 (zanidatamab) and ZW-49. He holds a Bachelor of Science in Biochemistry from the University of British Columbia, a Baccalaureate Diploma in Clinical Cytogenetics from the British Columbia Institute of Technology and a Master of Business Administration from Kellogg School of Management, Northwestern University.